EVŌQ Bio is developing an antimicrobial platform with applications in pharmaceutical and medical/surgical applications.

Our antimicrobial therapeutic demonstrates efficacy against the worst of the world’s antibiotic resistant bacteria. Our uniquely elegant mechanism of action provides a biotechnology platform to create precise novel product outcomes for numerous applications and allows for multiple drug administration pathways.

Our key ingredient for an inhaled respiratory therapeutic—our primary focus—is now in its late-stage pre-clinical phase as we initiate our FDA path. Pre-clinical studies indicate our active pharmaceutical ingredient is non-toxic to lung epithelial cells and penetrates lung sputum to kill bacteria, rivaling tobramycin as a therapeutic. Furthermore, in vitro testing shows no development of compound resistance to our asset, demonstrating efficacy up to 21 days.

EVŌQ Bio’s API permeates biofilm, a protective environment for bacteria. Biofilm allows bacteria to thrive and become drug-resistant in a way that changes the physical nature of the biofilm, thus further protecting the bacteria.

In May 2019 we received a prestigious grant from the Cystic Fibrosis Foundation to better understand the effect of our therapeutic on the microbes that pose the greatest threats to CF patients. We partnered with Seattle Children’s Hospital and the University of Washington to conduct our studies. In October 2021 we received an additional grant from CFF to continue our research.